Immune Responses Elicited by the GEN-003 Candidate HSV-2 Therapeutic Vaccine in a Randomized Controlled Dose-Ranging Phase 1/2a Trial

Flechtner et al., Vaccine (2016) - PMID: 27642130

Product(s) used in this publication: PepMix™ Peptide Pools



GEN-003 is a candidatetherapeuticHSV-2vaccine containing a fragment of infected cell protein 4 (ICP4.2), a deletion mutant of glycoprotein D2 (gD2ΔTMR), and Matrix-M2 adjuvant. In a dose-rangingphase1/2a clinical trial, immunization with GEN-003 reduced viral shedding and the percentage of reported herpetic lesion days. Here we examine the immuneresponses in the same trial, to characterize vaccine-related changes in antibody and cell-mediated immunity.


Participants with genital HSV-2 infection were randomized to 1 of 3 doses of GEN-003, antigens without adjuvant, or placebo. Subjects received 3 intramuscular doses, three weeks apart, and were monitored for viral shedding, lesions and immunogenicity. Antibody titers were measured by ELISA and neutralization assay in serum samples collected at baseline and 3weeks post each dose. T cell responses were assessed pre-immunization and 1week post each dose by IFN-γ ELISpot and intracellular cytokine staining. Blood was also collected at 6 and 12months to monitor durability of immuneresponses.


Antibody and T cell responses increased with vaccination and were potentiated by adjuvant. Among the doses tested, the rank order of reduction in viral shedding follows the ranking of fold change from baseline in T cell responses. Some immuneresponses persisted up to 12months.


All measures of immunity are increased by vaccination with GEN-003; however, a correlate of protection is yet to be defined.

Copyright © 2016. Published by Elsevier Ltd.


Herpes simplex virus; Immune response; Immunotherapy; Vaccine

Stay in touch and be the first to receive the latest news!